# Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

> **NCT05513391** · PHASE3 · TERMINATED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 366 (actual)

## Conditions studied

- Influenza Immunization

## Interventions

- **BIOLOGICAL:** Recombinant influenza vaccine (RIV4)
- **BIOLOGICAL:** Quadrivalent influenza vaccine (IIV4)

## Key facts

- **NCT ID:** NCT05513391
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-10
- **Primary completion:** 2023-10-03
- **Final completion:** 2023-10-03
- **Target enrollment:** 366 (ACTUAL)
- **Why stopped:** Sponsor decision to prematurely stop the study. This decision was made without any safety concerns.
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05513391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05513391, "Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05513391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*